Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy

Tuberculosis Infection Clinical Trial

Official title:

Open Label, Single Center, Phase 1 Dose Escalation and Extension Trial to Evaluate Safety and Tolerability of Chlorquine as Adjuvant Drug to Standard 4-drug Anti-tuberculosis Therapy in Healthy Volunteers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05443178
• Other study ID #: Clear TB
• Status: Recruiting
• Phase: Phase 1
• Start date: January 4, 2022
• Est. completion date: December 1, 2024

Study information

• Verified date: December 2023
• Source: University of Zurich
• Contact: Khadija M'Rabet, Dr. med.
• Phone: +41 44 255 13 65
• Email: Khadija.MRabet-Bensalah[@]usz.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In vitro and in vivo data show promising results of adjunctive use of Chloroquine to standard tuberculosis therapy as Chloroquine enhances animicrobial effectiveness against intracellular MTB. To date, no safety data of the concurrent use of both treatments is availble. In a phase I trial, the investigators aim to evaluate safety and tolerability of the concurrent use of Chloroquine and standard anti-TB drug in healthy volunteers.

Description:

Even though tuberculosis (TB) remains one of the top 10 causes of death worldwide in 2019, there exists a gap in development of new diagnostics and treatments. There is a substantial need for new TB regimens, which would ideally be shorter, more tolerable and more efficient in eradicating all subpopulations of mycobacterium tuberculosis (MTB). In this regard, a promising TB drug pipeline emerges through re-use of marketed non TB-drugs, re-engineering of existing anti-TB compounds and discovery of new compounds. In vitro data showed that Chloroquine (CQ) inhibits an efflux pump expressed on macrophages. Inhibition of this pump increases intracellular concentration of Isoniazid and Pyrazinamide and enhances antimicrobial effectiveness against intracellular MTB. Recently published in vivo mouse model data confirmed the positive effect of CQ combined with the standard anti-TB therapy. In line with global attempts to enhance effectiveness and shorten TB therapy, the investigators propose to evaluate this combination in a clinical setting. The absence of clinical study data showing safety and tolerability of CQ administered with first-line anti-TB drugs in humans shows the need for the research team to conduct this study. the investigators hypothesize that additional CQ to standard 4-drug anti-TB therapy is safe and increases the efficacy against intracellular MTB, leading to a pronounced reduction of the intracellularly hiding bacteria and overall to an accelerated reduction of bacterial load. The major advantages of this new combination with CQ and the 4-drug anti-TB therapy are, that all substances are long-term approved, commercially available drugs and that effective CQ concentrations are well achievable in humans. Primary objective of the study is to investigate the safety and tolerability of a combination of standard doses of Nivaquine® (Chloroquine) with standard doses of Rimstar® (4-drug anti-TB therapy) in healthy volunteers. Secondary objective of the study is to assess drug concentration of the new combination (Nivaquine® and Rimstar®) in healthy volunteers over time.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 16
• Est. completion date: December 1, 2024
• Est. primary completion date: July 4, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion criteria:

1. Informed study-specific consent (including possible pharmacogenetic analysis) as documented by signature

2. Healthy volunteers aged between 18 and 50 years of age (significantly increased risk of side effects from 50 years of age with Rimstar®)

Exclusion criteria:

1. Lack of highly effective contraception during the study treatment and for 8 months after the last dose of study treatment (until Day 254, visit 7) according to 11.4 with

the following consideration for participating women:

• From Day 1 (visit 2) up to Day 30 (visit 6) hormonal contraception is insufficient due to lower concentrations of estrogen and/or gestagen during and up to 14 days after Rimstar® intake. The hormonal contraception must be supplemented with a barrier method (preferably male condom).
• From Day 30 (visit 6) up to Day 254 (visit 7) hormonal contraceptive methods can be used and are considered highly effective.

2. Pregnant or lactating females

3. Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product, glucose-6-phosphate dehydrogenase insufficiency (favism)

4. Regular treatment with drugs in the last 14 days prior to first intake of study drug (except for Paracetamol and Vitamin B6 (pyridoxine), see 8.7).

5. History of or concurrent, clinically significant cardiac, immunological, pulmonary, neurological, renal, gastrointestinal, dermatological, endocrinological or other major disease as determined by the Investigator and/or his representative

6. History of or presence of any clinically significant abnormality in vital signs, ECG, or laboratory test results or has any medical or psychiatric condition that, in the opinion of the Investigator, may interfere with the study procedures or compromise subject safety

7. History of or currently present retinopathy or other disturbances of the field of vision or the retina according to the Investigator

8. History of alcohol or substance abuse for the last 3 months prior to Screening, as determined by the Investigator

9. Weight less than 55kg

10. Intake of grapefruit juice or grapefruits within 2 weeks before the first study drug administration and during treatment phase

11. Donation of blood or blood products within a 30-day period prior to Screening

12. Current enrolment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months of participation to the Clear trial.

13. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant

14. The investigator, his/her family members, employees and other dependent persons

Related Conditions & MeSH terms

• Latent Tuberculosis
• Tuberculosis
• Tuberculosis Infection

Intervention

Drug:
• Nivaquine ® (Chloroquine)
dose escalation and extension trial

Locations

Country	Name	City	State
Switzerland	Clinical Trial Center	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Physicial examination 1.1	Heart auscultation (normal/abnormal)	day 14
Primary	Physicial examination 1.2	Heart auscultation (normal/abnormal)	day 30
Primary	Physicial examination 2.1	lung auscultation (normal, abnormal)	day 14
Primary	Physicial examination 2.2	lung auscultation (normal, abnormal)	day 30
Primary	Physicial examination 3.1	abdominal examination (normal, abnormal)	day 14
Primary	Physicial examination 3.2	abdominal examination (normal, abnormal)	day 30
Primary	Physicial examination 4.1	lymph node palpation (normal, abnormal)	day 14
Primary	Physicial examination 4.2	lymph node palpation (normal, abnormal)	day 30
Primary	Physicial examination 5.1	reflex testing (normal, abnormal)	day 14
Primary	Physicial examination 5.2	reflex testing (normal, abnormal)	day 30
Primary	Physicial examination 6.1	test vibration sense with tuning fork (mallelor left and right X/8)	day 14
Primary	Physicial examination 6.2	test vibration sense with tuning fork (mallelor left and right X/8)	day 30
Primary	Vital Signs 1.1	heart rate (beats/min)	day 1
Primary	Vital Signs 1.2	heart rate (beats/min)	day 7
Primary	Vital Signs 1.3	heart rate (beats/min)	day 14
Primary	Vital Signs 1.4	heart rate (beats/min)	day 15
Primary	Vital Signs 1.5	heart rate (beats/min)	day 30
Primary	Vital Signs 2.1	blood pressure (mmHg)	day 1
Primary	Vital Signs 2.2	blood pressure (mmHg)	day 7
Primary	Vital Signs 2.3	blood pressure (mmHg)	day 14
Primary	Vital Signs 2.4	blood pressure (mmHg)	day 15
Primary	Vital Signs 2.5	blood pressure (mmHg)	day 30
Primary	Vital Signs 3.1	temperature (°C)	day 1
Primary	Vital Signs 3.2	temperature (°C)	day 7
Primary	Vital Signs 3.3	temperature (°C)	day 14
Primary	Vital Signs 3.4	temperature (°C)	day 15
Primary	Vital Signs 3.5	temperature (°C)	day 30
Primary	Safety Laboratory samples Panel 1.1	Sodium (mmol/l)	day 1
Primary	Safety Laboratory samples Panel 1.2	Sodium (mmol/l)	day 7
Primary	Safety Laboratory samples Panel 1.3	Sodium (mmol/l)	day 14
Primary	Safety Laboratory samples Panel 1.4	Sodium (mmol/l)	day 30
Primary	Safety Laboratory samples Panel 2.1	Potassium (mmol/l)	day 1
Primary	Safety Laboratory samples Panel 2.2	Potassium (mmol/l)	day 7
Primary	Safety Laboratory samples Panel 2.3	Potassium (mmol/l)	day 14
Primary	Safety Laboratory samples Panel 2.4	Potassium (mmol/l)	day 30
Primary	Safety Laboratory samples Panel 3.1	Calcium (mmol/l)	day 1
Primary	Safety Laboratory samples Panel 3.2	Calcium (mmol/l)	day 7
Primary	Safety Laboratory samples Panel 3.3	Calcium (mmol/l)	day 14
Primary	Safety Laboratory samples Panel 3.4	Calcium (mmol/l)	day 30
Primary	Safety Laboratory samples Panel 4.1	Creatinine (umol/l)	day 1
Primary	Safety Laboratory samples Panel 4.2	Creatinine (umol/l)	day 7
Primary	Safety Laboratory samples Panel 4.3	Creatinine (umol/l)	day 14
Primary	Safety Laboratory samples Panel 4.4	Creatinine (umol/l)	day 30
Primary	Safety Laboratory samples Panel 5.1	Total Bilirubin (umol/l)	day 1
Primary	Safety Laboratory samples Panel 5.2	Total Bilirubin (umol/l)	day 7
Primary	Safety Laboratory samples Panel 5.3	Total Bilirubin (umol/l)	day 14
Primary	Safety Laboratory samples Panel 5.4	Total Bilirubin (umol/l)	day 30
Primary	Safety Laboratory samples Panel 6.1	ALT (U/l)	day 1
Primary	Safety Laboratory samples Panel 6.2	ALT (U/l)	day 7
Primary	Safety Laboratory samples Panel 6.3	ALT (U/l)	day 14
Primary	Safety Laboratory samples Panel 6.4	ALT (U/l)	day 30
Primary	Safety Laboratory samples Panel 7.1	Glucose (mmol/l)	day 1
Primary	Safety Laboratory samples Panel 7.2	Glucose (mmol/l)	day 7
Primary	Safety Laboratory samples Panel 7.3	Glucose (mmol/l)	day 14
Primary	Safety Laboratory samples Panel 7.4	Glucose (mmol/l)	day 30
Primary	Safety Laboratory samples Panel 8.1	CRP (mg/l)	day 1
Primary	Safety Laboratory samples Panel 8.2	CRP (mg/l)	day 7
Primary	Safety Laboratory samples Panel 8.3	CRP (mg/l)	day 14
Primary	Safety Laboratory samples Panel 8.4	CRP (mg/l)	day 30
Primary	Safety Laboratory samples Panel 9.1	Haemoglobin (g/l)	day 1
Primary	Safety Laboratory samples Panel 9.2	Haemoglobin (g/l)	day 7
Primary	Safety Laboratory samples Panel 9.3	Haemoglobin (g/l)	day 14
Primary	Safety Laboratory samples Panel 9.4	Haemoglobin (g/l)	day 30
Primary	Safety Laboratory samples Panel 10.1	Platlets (G/l)	day 1
Primary	Safety Laboratory samples Panel 10.2	Platlets (G/l)	day 7
Primary	Safety Laboratory samples Panel 10.3	Platlets (G/l)	day 14
Primary	Safety Laboratory samples Panel 10.4	Platlets (G/l)	day 30
Primary	Safety Laboratory samples Panel 11.1	White blood cell (G/l)	day 1
Primary	Safety Laboratory samples Panel 11.2	White blood cell (G/l)	day 7
Primary	Safety Laboratory samples Panel 11.3	White blood cell (G/l)	day 14
Primary	Safety Laboratory samples Panel 11.4	White blood cell (G/l)	day 30
Primary	Safety Laboratory samples Panel 12.1	Blood pregnancy test (Blood beta-hCG)	day 7
Primary	Safety Laboratory samples Panel 12.2	Blood pregnancy test (Blood beta-hCG)	day 30
Primary	Urinanalysis 1.1	Dipstick: protein negative/+/++/+++	day 1
Primary	Urinanalysis 1.2	Dipstick: protein negative/+/++/+++	day 7
Primary	Urinanalysis 1.3	Dipstick: protein negative/+/++/+++	day 14
Primary	Urinanalysis 1.4	Dipstick: protein negative/+/++/+++	day 30
Primary	Urinanalysis 2.1	Dipstick: white blood cells negative/+/++/+++	day 1
Primary	Urinanalysis 2.2	Dipstick: white blood cells negative/+/++/+++	day 7
Primary	Urinanalysis 2.3	Dipstick: white blood cells negative/+/++/+++	day 14
Primary	Urinanalysis 2.4	Dipstick: white blood cells negative/+/++/+++	day 30
Primary	Urinanalysis 3.1	Dipstick: red blood cells negative/+/++/+++	day 1
Primary	Urinanalysis 3.2	Dipstick: red blood cells negative/+/++/+++	day 7
Primary	Urinanalysis 3.3	Dipstick: red blood cells negative/+/++/+++	day 14
Primary	Urinanalysis 3.4	Dipstick: red blood cells negative/+/++/+++	day 30
Primary	Urinanalysis 4.1	Dipstick: Glucose negative/+/++/+++	day 1
Primary	Urinanalysis 4.2	Dipstick: Glucose negative/+/++/+++	day 7
Primary	Urinanalysis 4.3	Dipstick: Glucose negative/+/++/+++	day 14
Primary	Urinanalysis 4.4	Dipstick: Glucose negative/+/++/+++	day 30
Primary	Safety 12 lead ECG 1.1	Rate/min	day 7
Primary	Safety 12 lead ECG 1.2	Rate/min	30
Primary	Safety 12 lead ECG 2.1	Rhythm (regular/irregular)	day 7
Primary	Safety 12 lead ECG 2.2	Rhythm (regular/irregular)	day 30
Primary	Safety 12 lead ECG 3.1	PQ interval (ms)	day 7
Primary	Safety 12 lead ECG 3.3	PQ interval (ms)	day 30
Primary	Safety 12 lead ECG 4.1	QRS interval (ms)	day 7
Primary	Safety 12 lead ECG 4.2	QRS interval (ms)	day 30
Primary	Safety 12 lead ECG 5.1	ST Segment (normal/elevation/depression)	day 7
Primary	Safety 12 lead ECG 5.2	ST Segment (normal/elevation/depression)	day 30
Primary	Safety ophtalmological examination 1.1	Slit lamp examaniation both sides (normal/abnormal)	day 30
Primary	Safety ophtalmological examination 1.2	Refraction both sides (+/-)	day 30
Primary	Safety ophtalmological examination 1.3	Biomicroscopy of the central fundus both sides(normal/abnormal)	day 30
Primary	Safety ophtalmological examination 1.4	Applanation tonometry and stereoscopic papilla evaluation bilateral (normal/abnormal), Color sense test according to Panel D-15 right and left side (normal/abnormal)	day 30
Primary	Safety ophtalmological examination 1.5	Color sense test according to Panel D-15 bilateral (normal/abnormal)	day 30
Primary	Occurence of adverse events and serious adverse events 1.1	according to GCP Guideline	day 1
Primary	Occurence of adverse events and serious adverse events 1.2	according to GCP Guideline	day 7
Primary	Occurence of adverse events and serious adverse events 1.3	according to GCP Guideline	day 14
Primary	Occurence of adverse events and serious adverse events 1.4	according to GCP Guideline	day 15
Primary	Occurence of adverse events and serious adverse events 1.5	according to GCP Guideline	day 30
Primary	Occurence of adverse events and serious adverse events 1.6	according to GCP Guideline	day 256
Secondary	Drug concentration over time measured by the pharmacokinetics	drug concentration (mg/l) of Rifampicin, Isoniazid, 25-O-Desacetylrifampicin, Ethambutol, Pyrazinamide, Chloroquine, Desethylchloroquine	day 14 prior to dosing (-15 until -5 minutes) and 1, 2, 4, 6 and 24 hours after dosing